Universal flu pitch Position EnGen Bio as a pioneer in universal Type A flu vaccines with potential for long-term immunity across seasonal and pandemic strains, highlighting a sizeable addressable market in both human and veterinary sectors and the prospect of reducing global flu burden.

Early-stage partnership Target early-stage biotech, venture investors, and crowdfunding platforms as potential funding channels that align with EnGen Bio’s recent financing activity, emphasizing growth potential and the strategic value of additional capital for R&D and clinical milestones.

Therapeutic potential Explore opportunities with pharmaceutical distributors and healthcare providers by stressing not only preventive vaccines but also the antibody-based therapeutic avenue with a sizable $2B market potential, broadening collaboration possibilities beyond vaccines.

Global health positioning Leverage WHO urgency for universal flu vaccines and the global pandemic risk to create partner pitches focused on public-private collaboration, government programs, and grant-funded initiatives that can accelerate development and market entry.

Small company agility Highlight EnGen Bio’s lean team and rapid decision-making as a selling point for fast-tracked pilots, co-development deals, and milestone-driven collaborations with larger pharma companies seeking innovative influenza solutions.